Alpha Teknova stock
TKNONASDAQAlpha Teknova, Inc., HealthcareISIN US02080L1026
43Score 43 out of 100, Weak
Price and trend
83 / 100
Price history
+86% in one yearThe chart shows daily closes over 5 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 63% above it.
Since June 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 69).
The price is 11% below its 52-week high. Largest decline in 5 years: 96% (June 2021 to July 2024).
Chart figures for advanced users
- SMA 50$7.83
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$5.09
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)69
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$1.99
- The lowest closing price of the last twelve months.
- Resistance$9.33
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Alpha Teknova, Inc. belongs to the Drug Manufacturers (Specialty & Generic) industry (United States) and, with a market value of $520.6M, is number 71 of 78 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $40.52M (up 7.4% year on year) and a loss of $17.26M.
- For fiscal 2026, analysts expect on average revenue of $46.01M (up 13.5%) and adjusted earnings per share of −$0.30.
Show more
- MEQIRI Score 43 out of 100 (Weak): rank 514 of 714 in Healthcare, median 53.
- Our model puts fair value at $3.51, with the price 146% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
None of our strength checks applies.
Weaknesses
- DilutionShare count up 91% since 2021.Capital allocation 18
- Above fair valuePrice 146% above the fair value of $3.51.Valuation 25
- Loss-makingLoss of $15.97M over the last 12 months.Fundamentals 17
Its standout strengths are momentum and technical analysis, while capital allocation and fundamentals hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
- high price swings
- price up very strongly over the past year
What lowers it
- stable momentum
Valuation
Valuation signal
Significantly overvaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $2.34 and expensive above $7.02 (uncertainty very high, based on the price swings of the past year).
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $2.86, at 7.8% it would be $4.49.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 15.4% on the twelve months before. Revenue has grown strongly since 2019, at around 12% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 33%, operating −42%, net −43%. Last 12 months: net −35%.
Debt & balance sheet
Fiscal 2025Debt is low, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 25 Feb 2027in 105 days
- Last reported
- 4 Nov 2026EPS reported −$0.06 (expected −$0.07)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −$0.300.0%
- Revenue
- $46.01M0.0%
- Earnings per share
- −$0.260.0%
- Revenue
- $52.68M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +7.0%2026 revenue guidance of $42 million to $44 million reiterated, gross margin in the mid 30% range.
“Turning to our 2026 guidance and outlook, we are reiterating our 2026 total revenue guidance of $42 million to $44 million.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 6 May 2026 (fiscal Q1 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases or sales in the last 6 months.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Alpha Teknova
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 43
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (Specialty & Generic)
The next larger and next smaller companies by market value
- PharmanutraPHN.MI $906.68M62
- Ironwood PharmaceuticalsIRWD $806.23M71
- Collegium PharmaceuticalCOLL $770.98M52
- EvotecEVT.DE $624.43M32
- EvolusEOLS $491.12M45
- KamadaKMDA $468.95M66
- Aquestive TherapeuticsAQST $449.96M29
- BoironBOI.PA $371.89M56
ETFs that hold Alpha Teknova
Held by 3 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.03% | 0.35% | €1.21B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.00% | 0.30% | €4.22B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.00% | 0.30% | €2.17B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Jun 2022)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.